Patents by Inventor Berwyn Ewart Clarke

Berwyn Ewart Clarke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimaeric hepadnavirus core antigen proteins
    Publication number: 20030175296
    Abstract: Particles, useful as a delivery system for an epitope, are composed of a chimaeric hepadnavirus core antigen protein wherein a foreign amino acid sequence comprising an epitope is inserted in or replaces all or part of the sequence of amino acid residues from 68 to 90 in the case where the core antigen is hepatitis B core antigen or the corresponding amino acid sequence in the case of the core antigen of another hepadnavirus.
    Type: Application
    Filed: September 23, 2002
    Publication date: September 18, 2003
    Applicant: BURROUGHS WELLCOME CO.
    Inventors: Alan Louis Brown, Berwyn Ewart Clarke, David John Rowlands
  • Fusion proteins
    Patent number: 6194546
    Abstract: A DNA sequence encoding a fusion protein comprising influenza virus HA, at a site of which normally occupied by a natural antigenic epitope thereof a different antigenic epitope is provided, is incorporated in a vector which is capable of expressing the fusion protein when provided in a eucaryotic host. When in the form of a viral vector such as a recombinant vaccinia virus, the vector can be used as a vaccine. Alternatively, the fusion protein expressed by the host can be recovered and provided as a vaccine.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: February 27, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Susan Elizabeth Newton, Berwyn Ewart Clarke
  • Fusion proteins
    Patent number: 5700680
    Abstract: A DNA sequence encoding a fusion protein comprising influenza virus HA, at a site of which normally occupied by a natural antigenic epitope thereof a different antigenic epitope is provided, is incorporated in a vector which is capable of expressing the fusion protein when provided in a eucaryotic host. When in the form of a viral vector such as a recombinant vaccinia virus, the vector can be used as a vaccine. Alternatively, the fusion protein expressed by the host can be recovered and provided as a vaccine.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 23, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Susan Elizabeth Newton, Berwyn Ewart Clarke